anonymous
Guest
anonymous
Guest
Our entire defense is to tell doctors we cannot compare the two drugs and pivot back to our 8 year old messaging?
As engaging and inspiring as that is, maybe we should get advice from a company who has launched a highly competitive me too drug.
This is not a successful plan.
Docs will want to know the similarities, differences and where they should use both. We lose the LTC scripts without crushable so where do we gain ground?
As engaging and inspiring as that is, maybe we should get advice from a company who has launched a highly competitive me too drug.
This is not a successful plan.
Docs will want to know the similarities, differences and where they should use both. We lose the LTC scripts without crushable so where do we gain ground?